In summary, our study has demonstrated a new therapeutic strategy for inhibiting cancer growth with dual-targeting antioxidant mechanisms and mitophagy using a NUAK1/ULK1 dual inhibitor, MRT68921. This evidence concerns the gene ULK1 and cancer.